Can-Fite BioPharma’s (CANF) Buy Rating Reiterated at HC Wainwright

Posted by Patrick Bannon on May 9th, 2024

Can-Fite BioPharma (NYSE:CANF – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report issued on Thursday, Benzinga reports. They currently have a $18.00 target price on the stock.

Separately, StockNews.com initiated coverage on Can-Fite BioPharma in a research note on Wednesday. They issued a “hold” rating on the stock.

View Our Latest Stock Report on Can-Fite BioPharma

Can-Fite BioPharma Stock Performance

Shares of CANF stock traded up $0.12 on Thursday, reaching $2.14. The stock had a trading volume of 150,245 shares, compared to its average volume of 20,334. The stock has a market cap of $7.58 million, a P/E ratio of -1.15 and a beta of 1.58. Can-Fite BioPharma has a 1 year low of $1.81 and a 1 year high of $3.33. The company has a 50 day simple moving average of $2.14 and a 200 day simple moving average of $2.10.

Can-Fite BioPharma (NYSE:CANF – Get Free Report) last announced its earnings results on Thursday, March 28th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04). Can-Fite BioPharma had a negative net margin of 1,027.46% and a negative return on equity of 113.75%. The business had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.20 million. On average, equities research analysts anticipate that Can-Fite BioPharma will post -0.03 earnings per share for the current fiscal year.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently bought a new stake in Can-Fite BioPharma stock. Schechter Investment Advisors LLC purchased a new stake in Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund purchased 20,077 shares of the company’s stock, valued at approximately $44,000. Schechter Investment Advisors LLC owned about 0.57% of Can-Fite BioPharma as of its most recent filing with the SEC. Institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

(Get Free Report)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.